Bacterial infections in cirrhosis: A growing problem with significant implications

Clinical Liver Disease

Volumn 2, Issue 3, 2013, Pages 102-105

  Fernandez, Javier ^a   Arroyo, Vicente ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CARBAPENEM; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DAPTOMYCIN; FOSFOMYCIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; MOXIFLOXACIN; NITROFURANTOIN; NORFLOXACIN; PROCALCITONIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT;

ABDOMINAL RADIOGRAPHY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ASCITES; ASCITES FLUID ANALYSIS; BACTERIAL INFECTION; BACTERIAL PERITONITIS; CELLULITIS; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIFFERENTIAL DIAGNOSIS; DRUG INDICATION; DRUG SENSITIVITY; EARLY DIAGNOSIS; ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFLAMMATION; LIVER CIRRHOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PATIENT SELECTION; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SECONDARY INFECTION; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN SUSCEPTIBLE ENTEROCOCCUS; ANTIBIOTIC THERAPY; ASCITES FLUID; BLOOD CULTURE; COMMUNITY ACQUIRED INFECTION; ENTEROCOCCUS; HEPATORENAL SYNDROME; NONHUMAN; PARACENTESIS; THORAX RADIOGRAPHY; URINE CULTURE; URINE SEDIMENT;

EID: 84901242330     PISSN: None     EISSN: 20462484     Source Type: Journal    
DOI: 10.1002/cld.169     Document Type: Review

References (10)

1. Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012: S1- S12.
2. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26-42.
3. Arvaniti V, D'Amcio G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-1256.
4. Fernández J, Acevedo J, Castro M, Garcia O, Rodriguez de Lopez C, Roca D, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-1561.
5. Soriano G, Castellote J, Alvarez C, Girbau A, Gordillo J, Baliellas C, et al. Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. J Hepatol 2010; 52: 39-44.
6. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
7. Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087- 2107.
8. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz del Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 5: 403-409.
9. Fernandez J, Ruiz del Arbol L, Gomez C, Durandez R, Serradilla R, Guarner C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131: 1049-1056.
10. Fernandez J, Navasa N, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824.